ABEO
Abeona Therapeutics Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-26/100
Last price
5.04
▼ 0.07 (1.37%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
5.00
Prev close
5.11
Day high
5.16
Day low
4.89
Volume
1.42M
Market cap
$286.49M
P/E (TTM)
—
52W range
4.00 – 7.65
Day trading desk
Gap from prior close
-2.15%
Prior close 5.11
VWAP
5.01
+0.63% from price
Relative volume
1.68×
Unusually busy
Session range
13.31%
4.81 – 5.45
Position in range
36%
Mid range
ATR (14D)
0.23
4.49% of price
Prior day high
5.16
PDH
Prior day low
4.99
PDL
Bid / ask spread
—
Quote not published
Session volume
2.40M
Avg 1.43M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.91%
-4.9%
1M
-16.50%
-17.7%
3M
-26.32%
-30.8%
6M
+4.16%
-14.0%
YTD
-4.93%
-19.2%
1Y
-7.39%
-23.8%
3Y
+19.00%
-63.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ABEO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-367.70K
Net selling
Buy transactions
1
500 shares
Sell transactions
19
368.20K shares
Net transactions
+20
Buys less sells
Sell : buy shares
736.4 : 1
Heavily one-sided
Insider-held shares
6.27M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 29, 26 | VAZZANO JOSEPH WALTER Chief Financial Officer |
SELL | 9.19K | $47.38K | Direct |
| Sep 29, 26 | SESHADRI VISHWAS Chief Executive Officer |
SELL | 19.61K | $101.09K | Direct |
| Sep 29, 26 | O'MALLEY BRENDAN M Officer |
SELL | 6.73K | $34.68K | Direct |
| Sep 29, 26 | VASANTHAVADA MADHAV Officer |
SELL | 4.90K | $25.27K | Direct |
| Sep 1, 26 | ALVINO MARK J. Director |
SELL | 15.00K | $87.97K | Direct |
| Jul 21, 26 | VAZZANO JOSEPH WALTER Chief Financial Officer |
SELL | 1.48K | $9.65K | Direct |
| Jul 9, 26 | VAZZANO JOSEPH WALTER Chief Financial Officer |
SELL | 24.88K | $173.26K | Direct |
| Jul 9, 26 | SESHADRI VISHWAS Chief Executive Officer |
SELL | 67.97K | $473.33K | Direct |
| Jul 9, 26 | O'MALLEY BRENDAN M Officer |
SELL | 12.05K | $83.91K | Direct |
| Jul 9, 26 | VASANTHAVADA MADHAV Officer |
SELL | 12.61K | $87.78K | Direct |
| Jun 30, 26 | ALLAND LEILA Director |
SELL | 11.00K | $65.09K | Direct |
| Jun 15, 26 | SILVERSTEIN CHRISTINE BERNI Director |
SELL | 18.16K | $103.69K | Direct |
| Jun 9, 26 | VAZZANO JOSEPH WALTER Chief Financial Officer |
SELL | 49.34K | $265.24K | Direct |
| Jun 9, 26 | SESHADRI VISHWAS Chief Executive Officer |
SELL | 56.34K | $301.92K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALLAND LEILA |
Director | 162.61K | Sale |
AMOROSO MICHAEL |
Director | 217.78K | Stock Award(Grant) |
CHARLES FAITH L. |
Director | 176.41K | Stock Award(Grant) |
O'MALLEY BRENDAN M |
Officer | 421.23K | Sale |
SESHADRI VISHWAS |
Chief Executive Officer | 1.29M | Sale |
SILVERSTEIN CHRISTINE BERNI |
Director | 119.56K | Sale |
VASANTHAVADA MADHAV |
Officer | 285.72K | Sale |
VAZZANO JOSEPH WALTER |
Chief Financial Officer | 482.89K | Sale |
WUCHTERL DONALD A |
Director | 167.94K | Sale |
ZEIHER BERNHARDT G |
Director | 84.46K | Stock Award(Grant) |
Fundamentals
Market cap$286.49M
Enterprise value$159.54M
Revenue (TTM)$25.52M
Gross profit$-10.18M
EBITDA$-80.79M
Net income$-62.89M
EPS (TTM)$-1.18
Free cash flow$-73.40M
Total cash$146.83M
Total debt$19.87M
Book value / share$2.24
Shares outstanding57.18M
Float36.85M
Short % of float29.55%
Dividend yield0.00%
Beta (5Y)1.30
Valuation & profitability ratios
Trailing P/E—
Forward P/E-24.14
PEG ratio—
Price / sales—
Price / book2.24
EV / revenue6.25
EV / EBITDA-1.98
Gross margin-39.90%
Operating margin-119.97%
Profit margin-246.42%
Return on equity-43.13%
Return on assets-24.55%
Debt / equity15.52
Current ratio6.64
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $5.82M | $0 | $3.50M | $1.41M | — |
| Operating revenue | $3.40M | $0 | $3.50M | $1.41M | — |
| Cost of revenue | $3.42M | $0 | $1.60M | $450.00K | — |
| Gross profit | $2.40M | $0 | $1.90M | $964.00K | — |
| Research & development | $26.81M | $34.36M | $31.09M | $28.96M | -22.0% |
| Selling, general & admin | $65.03M | $29.85M | $19.00M | $17.26M | +117.9% |
| Total operating expense | $91.84M | $64.21M | $50.09M | $46.22M | +43.0% |
| Operating income | -$89.45M | -$64.21M | -$48.20M | -$45.26M | -39.3% |
| Net interest income | $1.82M | $38.00K | $1.70M | -$305.00K | +4,678.9% |
| Pre-tax income | $71.28M | -$63.73M | -$54.19M | -$39.70M | +211.8% |
| Tax provision | $100.00K | $0 | — | — | — |
| Net income | $71.18M | -$63.73M | -$54.19M | -$39.70M | +211.7% |
| Net income to common | $71.18M | -$63.73M | -$54.19M | -$43.48M | +211.7% |
| Basic EPS | 1.34 | -1.55 | -2.53 | -5.53 | +186.5% |
| Diluted EPS | 1.01 | -1.55 | -2.53 | -5.53 | +165.2% |
| EBIT | $75.02M | -$59.53M | -$53.77M | -$38.96M | +226.0% |
| EBITDA | $78.59M | -$56.62M | -$50.57M | -$34.38M | +238.8% |
| Basic shares | 52.95M | 41.05M | 21.38M | 7.86M | +29.0% |
| Diluted shares | 66.14M | 41.05M | 21.38M | 7.86M | +61.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $78.44M | $23.36M | $14.47M | $14.22M | — | +235.8% |
| Cash & short-term investments | $191.40M | $97.72M | $52.23M | $52.15M | — | +95.9% |
| Accounts receivable | $6.15M | $0 | — | $0 | $3.00M | — |
| Inventory | $5.49M | $0 | — | — | — | — |
| Total current assets | $204.91M | $100.85M | $55.74M | $53.10M | — | +103.2% |
| Property, plant & equipment | $13.88M | $7.98M | $7.99M | $11.07M | — | +73.9% |
| Goodwill & intangibles | — | — | — | $0 | $1.38M | — |
| Total assets | $219.57M | $108.93M | $64.00M | $64.21M | — | +101.6% |
| Total current liabilities | $29.57M | $16.59M | $13.42M | $7.78M | — | +78.3% |
| Current debt | $12.22M | $5.93M | — | — | — | +106.2% |
| Long-term debt | $7.81M | $13.04M | — | — | — | -40.1% |
| Total debt | $24.97M | $23.05M | $5.40M | $7.63M | — | +8.3% |
| Total liabilities | $60.35M | $64.90M | $49.18M | $37.45M | — | -7.0% |
| Retained earnings | -$742.08M | -$813.26M | -$749.52M | -$695.34M | — | +8.8% |
| Shareholder equity | $159.22M | $44.03M | $14.83M | $26.76M | — | +261.6% |
| Working capital | $175.34M | $84.27M | $42.31M | $45.32M | — | +108.1% |
| Net tangible assets | $159.22M | $44.03M | $14.83M | $26.76M | — | +261.6% |
| Shares issued | 55.04M | 45.64M | 26.52M | 17.72M | — | +20.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $71.18M | -$63.73M | -$54.19M | -$39.70M | — | +211.7% |
| Depreciation & amortisation | $3.56M | $2.91M | $3.20M | $4.58M | — | +22.6% |
| Stock-based compensation | $10.78M | $6.63M | $4.77M | $3.05M | — | +62.6% |
| Change in working capital | -$5.39M | -$4.38M | -$1.79M | -$5.89M | — | -22.9% |
| Operating cash flow | -$76.33M | -$56.02M | -$37.01M | -$43.48M | — | -36.3% |
| Capital expenditure | -$7.97M | -$2.45M | -$331.00K | -$130.00K | — | -226.0% |
| Investing cash flow | $105.03M | -$39.24M | $208.00K | -$23.96M | — | +367.7% |
| Share buybacks | — | — | $0 | -$26.25M | $0 | — |
| Financing cash flow | $26.04M | $104.14M | $37.06M | $43.17M | — | -75.0% |
| Free cash flow | -$84.30M | -$58.46M | -$37.34M | -$43.61M | — | -44.2% |
| End cash position | $78.44M | $23.70M | $14.81M | $14.55M | — | +231.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $11.38M | $8.72M | $5.42M | $0 | $400.00K | — | +30.5% |
| Operating revenue | $11.38M | $8.72M | $3.00M | $0 | $400.00K | — | +30.5% |
| Cost of revenue | $4.18M | $2.70M | $2.84M | $488.00K | $100.00K | — | +54.9% |
| Gross profit | $7.20M | $6.02M | $2.58M | -$488.00K | $300.00K | — | +19.6% |
| Research & development | $5.02M | $9.55M | $6.71M | $4.22M | $5.94M | — | -47.5% |
| Selling, general & admin | $15.84M | $19.50M | $18.78M | $19.31M | $17.15M | — | -18.8% |
| Total operating expense | $20.86M | $29.06M | $25.49M | $23.53M | $23.09M | — | -28.2% |
| Operating income | -$13.65M | -$23.03M | -$22.91M | -$24.02M | -$22.79M | — | +40.7% |
| Net interest income | $659.00K | $524.00K | $663.00K | $771.00K | $70.00K | — | +25.8% |
| Pre-tax income | -$20.19M | -$17.07M | -$20.68M | -$20.36M | $124.34M | — | -18.3% |
| Tax provision | $0 | $2.00K | -$215.00K | -$15.20M | $15.51M | — | -100.0% |
| Net income | -$20.19M | -$17.07M | -$20.46M | -$5.16M | $108.83M | — | -18.2% |
| Net income to common | -$20.19M | -$17.07M | -$20.46M | -$5.16M | $108.83M | — | -18.2% |
| Basic EPS | -0.35 | -0.30 | — | -0.10 | 2.07 | -0.24 | -16.7% |
| Diluted EPS | -0.35 | -0.30 | — | -0.10 | 1.71 | -0.24 | -16.7% |
| EBIT | -$19.50M | -$16.24M | -$19.79M | -$19.46M | $125.30M | — | -20.0% |
| EBITDA | -$18.66M | -$15.37M | -$18.70M | -$18.57M | $126.07M | — | -21.4% |
| Basic shares | 57.05M | 56.62M | — | 54.24M | 52.52M | 49.78M | +0.8% |
| Diluted shares | 57.05M | 56.62M | — | 54.24M | 66.64M | 49.78M | +0.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $56.23M | $61.37M | $78.44M | $82.88M | $163.53M | -8.4% |
| Cash & short-term investments | $146.83M | $168.27M | $191.40M | $207.12M | $225.52M | -12.7% |
| Accounts receivable | $9.39M | $6.20M | $6.15M | — | — | +51.5% |
| Inventory | $5.92M | $6.05M | $5.49M | $4.85M | $2.69M | -2.2% |
| Total current assets | $164.58M | $182.99M | $204.91M | $216.13M | $232.26M | -10.1% |
| Property, plant & equipment | $14.10M | $14.68M | $13.88M | $14.42M | $13.63M | -4.0% |
| Total assets | $179.51M | $198.49M | $219.57M | $231.09M | $246.23M | -9.6% |
| Total current liabilities | $24.81M | $31.05M | $29.57M | $22.18M | $34.52M | -20.1% |
| Current debt | $13.33M | $13.33M | $12.22M | $8.89M | $5.56M | 0.0% |
| Long-term debt | $1.66M | $4.75M | $7.81M | $10.86M | $14.01M | -65.2% |
| Total debt | $19.87M | $23.17M | $24.97M | $24.11M | $24.08M | -14.2% |
| Total liabilities | $51.45M | $53.55M | $60.35M | $59.86M | $82.66M | -3.9% |
| Retained earnings | -$779.34M | -$759.15M | -$742.08M | -$721.62M | -$716.45M | -2.7% |
| Shareholder equity | $128.06M | $144.94M | $159.22M | $171.23M | $163.58M | -11.6% |
| Working capital | $139.77M | $151.94M | $175.34M | $193.95M | $197.75M | -8.0% |
| Net tangible assets | $128.06M | $144.94M | $159.22M | $171.23M | $163.58M | -11.6% |
| Shares issued | 57.23M | 56.87M | 55.04M | 52.40M | 51.25M | +0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$20.19M | -$17.07M | -$20.46M | -$5.16M | $108.83M | -18.2% |
| Depreciation & amortisation | $833.00K | $869.00K | $1.09M | $888.00K | $768.00K | -4.1% |
| Stock-based compensation | $3.37M | $2.96M | $2.56M | $2.69M | $2.83M | +13.9% |
| Change in working capital | -$9.01M | -$1.46M | -$593.00K | -$17.02M | $15.65M | -518.8% |
| Operating cash flow | -$17.50M | -$19.80M | -$17.95M | -$21.19M | -$18.78M | +11.7% |
| Capital expenditure | -$479.00K | -$935.00K | -$1.15M | -$2.52M | -$2.90M | +48.8% |
| Investing cash flow | $15.69M | $4.96M | $9.55M | -$64.63M | $155.89M | +216.1% |
| Financing cash flow | -$3.33M | -$2.22M | $3.61M | $5.16M | $10.49M | -50.1% |
| Free cash flow | -$17.98M | -$20.74M | -$19.11M | -$23.71M | -$21.68M | +13.3% |
| End cash position | $56.23M | $61.37M | $78.44M | $83.22M | $163.87M | -8.4% |
Options analytics
Put / call volume
2.52
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
1.00
-80.0% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
-24.2%
Calls bid over puts
Call volume
29
Contracts, this expiry
Put volume
73
Contracts, this expiry
Heaviest call OI
1.00
0 contracts
Heaviest put OI
3.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.25 | -0.35 | -42.9% |
| Mar 2026 | -0.39 | -0.30 | +23.7% |
| Dec 2025 | -0.37 | -0.37 | +2.2% |
| Sep 2025 | -0.34 | -0.11 | +68.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.17 | 4 | $14.82M | 0.0% |
| Next quarter | -0.13 | 4 | $17.70M | +226.6% |
| Current year | -0.95 | 4 | $52.63M | +804.3% |
| Next year | -0.21 | 4 | $115.62M | +119.7% |
Analyst targets & ownership
Mean target$18.88
High target$30.00
Low target$14.00
Implied upside274.50%
Analyst count8
ConsensusSTRONG BUY
Strong buy / Buy0 / 7
Hold0
Sell / Strong sell0 / 0
Held by insiders10.96%
Held by institutions74.90%
Institutions holding168
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
5.22
-3.49% from price
SMA 20
5.39
-7.08% from price
SMA 50
5.96
-15.90% from price
SMA 100
5.96
-15.49% from price
SMA 200
5.55
-9.75% from price
EMA 12
5.25
-3.97% from price
EMA 26
5.49
-8.26% from price
EMA 50
5.73
-12.02% from price
RSI (14)
33.7
Neutral
MACD (12,26,9)
-0.25
Hist -0.02
ATR (14)
0.23
4.52% of price
Realised vol 30D
36.4%
Annualised
Bollinger upper
5.86
20, 2σ
Bollinger lower
4.92
20, 2σ
50 / 200 cross
Golden
5.96 vs 5.55
Trend bias
Below 200
-9.75%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.48
More volatile than market
Correlation to SPY
0.36
Loosely linked
Realised vol 30D
36.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-32.8%
Peak to trough
Max drawdown 5Y
-90.7%
Peak to trough
ATR 14
0.23
4.52% of price
Beta (reported)
1.30
5Y monthly, from filing
Short interest
Shares short
15.75M
Prior 14.27M
Change vs prior
+10.3%
Shorts adding
% of float
29.55%
Heavily shorted
% of shares out
27.53%
Against total outstanding
Days to cover
13.0
Crowded exit
Float
36.85M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Sep 17, 26 | Roth Capital | INITIATED | — | Buy |
| Aug 14, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| May 28, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 19, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 13, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 18, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 15, 25 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Jul 16, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 14, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 16, 25 | Stifel | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:25
Split dateJul 5, 2022
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-15
Periodic Financial Reports
10-Q · 2026-08-13
Offering Registrations
S-8 · 2026-06-26
Corporate Changes & Voting Matters
8-K · 2026-06-12
Corporate Changes & Voting Matters
8-K · 2026-06-10
Corporate Changes & Voting Matters
8-K · 2026-06-04
Periodic Financial Reports
10-Q · 2026-05-13
Proxy Statements
DEFA14A · 2026-05-04
Headlines
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 5d ago
Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright
MarketBeat · 14d ago
Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum
MarketBeat · 15d ago
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
GlobeNewswire · 19d ago
ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells
Stocktwits · 19d ago
Sector Update: Healthcare Stocks Edge Higher Pre-Bell Wednesday
MT Newswires · 21d ago
Abeona Therapeutics Activates 8th ZEVASKYN Treatment Center in Florida
MT Newswires · 21d ago
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
GlobeNewswire · 21d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.